Journal of Neuropathology & Experimental Neurology:
DNA Methylation of Alzheimer Disease and Tauopathy-Related Genes in Postmortem Brain
Barrachina, Marta PhD; Ferrer, Isidre MD, PhD
From the Institut de Neuropatologia, Servei d'Anatomia Patològica, IDIBELL-Hospital Universitari de Bellvitge; and Universitat de Barcelona, L'Hospitalet de Llobregat, CIBERNED, Spain.
Send correspondence and reprint requests to: Isidre Ferrer, MD, PhD, Institut de Neuropatologia, Servei d'Anatomia Patològica, IDIBELL-Hospital Universitari de Bellvitge, carrer Feixa Llarga sn, 08907 L'Hospitalet de Llobregat, Spain; E-mail: firstname.lastname@example.org
This work was funded by the European Commission under the Sixth Framework Programme (BrainNet Europe II, LSHM-CT-2004-503039) and by FIS grants from the Spanish Ministry of Health, Instituto de Salud Carlos III (PI05/1631 and PI08/0582).
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.jneuropath.com).
DNA methylation occurs predominantly at cytosines that precede guanines in dinucleotide CpG sites; it is one of the most important mechanisms for epigenetic DNA regulation during normal development and for aberrant DNA in cancer. To determine the feasibility of DNA methylation studies in the postmortem human brain, we evaluated brain samples with variable postmortem artificially increased delays up to 48 hours. DNA methylation was analyzed in selected regions of MAPT, APP, and PSEN1 in the frontal cortex and hippocampus of controls (n = 26) and those with Alzheimer disease at Stages I to II (n = 17); Alzheimer disease at Stages III to IV (n = 15); Alzheimer disease at Stages V to VI (n = 12); argyrophilic grain disease (n = 10); frontotemporal lobar degeneration linked to tau mutations (n = 6); frontotemporal lobar degeneration with ubiquitin-immunoreactive inclusions (n = 4); frontotemporal lobar degeneration with motor neuron disease (n = 3); Pick disease (n = 3); Parkinson disease (n = 8); dementia with Lewy bodies, pure form (n= 5); and dementia with Lewy bodies, common form (n = 15). UCHL1 (ubiquitin carboxyl-terminal hydrolase 1 gene) was analyzed in the frontal cortex of controls and those with Parkinson disease and related synucleinopathies. DNA methylation sites were very reproducible in every case. No differences in the percentage of CpG methylation were found between control and disease samples or among the different pathological entities in any region analyzed. Because small changes in methylation of DNA promoters in vulnerable cells might have not been detected in total homogenates, however, these results should be interpreted with caution, particularly as they relate to chronic degenerative diseases in which small modifications may be sufficient to modulate disease progression.
DNA methylation is one of the most important mechanisms for epigenetic silencing in mammals; it occurs predominantly at cytosines that precede guanines in dinucleotide CpG sites (1). Approximately half of the human gene promoters contain CpG-rich regions with lengths of 0.5 kb to several kb known as CpG islands. Regions that are actively transcribed generally have promoter regions with predominantly unmethylated CpG islands, whereas transcriptionally silent regions have abundant methylated CpG sites (2). Most CpG islands are located in the 5′ UTR regions and the first exon (3). DNA methylation is a normal process that occurs in mammalian embryonic development, X-chromosome inactivation, and repression of proviral genes and endogenous transposons (1). Methylation of CpG islands is usually accompanied by posttranslational histone modifications that modulate gene expression (4, 5). For example, MeCP2 is a methyl CpG-binding protein that recruits members of chromatin remodeling complexes to repress gene transcription (6). Several mutations in MeCP2 genes have been reported in Rett syndrome, one of the most common genetic causes of mental retardation in females (7).
CpG islands are usually unmethylated in normal cells (8), whereas hypermethylation of CpG islands is a major event in many cancers (9). The role of DNA methylation in the brain is an emerging field of scientific analysis. It was recently reported that DNA methylation signatures exist for every cerebral region (10) and that neuronal DNA methylation is modified with life span (11).
The aims of this study were to 1) determine whether postmortem delay between death and tissue processing may affect CpG methylation, thus hampering further studies in the human postmortem brain; and 2) study DNA methylation in 5′ UTR and/or intronic regions of genes related to Alzheimer disease (AD) and other tauopathies, including Pick disease (PiD), argyrophilic grain disease (AGD), and frontotemporal lobar degeneration (FTLD) linked to mutations in tau (FTLD-tau). For the first purpose (and in line with previous studies focused on protein, RNA, and DNA preservation in postmortem carried out within the context of the European Brain Bank network [BrainNet Europe II] 12-14), we analyzed RAGE (advanced glycation end product receptor), ADORA2A (adenosine A2A receptor), and MAPT (tau) genes in brain samples with short and artificially prolonged postmortem delays. For the second purpose, CpG methylation in selected regions of MAPT, PSEN1 (presenilin 1 gene), and APP (β-amyloid precursor protein gene) were analyzed in the frontal cortex and hippocampus in AD cases at different stages of disease progression, AGD, and PiD. This was carried out in parallel with the study of age-matched controls and cases with other neurodegenerative diseases, including Parkinson disease (PD); dementia with Lewy bodies, pure and common forms (DLBp and DLBc); FTLD with ubiquitin- and TDP-43-immunoreactive inclusions not associated with motor neuron disease (FTLD-U-TDP-43); and FTLD associated with motor neuron disease (FTLD-MND). UCHL1 (ubiquitin carboxyl-terminal hydrolase 1 gene) was analyzed in the frontal cortex in PD and related synucleinopathies.
MATERIALS AND METHODS
To document variations in DNA methylation profiles with postmortem delay, we extracted genomic DNA from the frontal cortex of 5 different subjects obtained after a short postmortem delay and immediately frozen or stored at 4°C for 3, 6, 15.5, 24, or 48 hours and then frozen to mimic variable postmortem delay in tissue processing (Table 1).
Cases studied for CpG methylation in MAPT, PSEN1, APP, and UCHL1 were as follows: controls (n = 26), PD Stages 3 and 4 (n = 8), DLBp (n = 5), DLBc (n = 15), AD Stages I to II (n = 17), AD Stages III to IV (n = 15), AD Stages V to VI (n = 12), AGD (n = 10), FTLD-tau (n = 6), FTLD-U (n = 4), FTLD-MND (n = 3), and PiD (n = 3). The total number of cases was 124, with 75 males and 49 females. Postmortem delay was 2 to 20 hours. The neuropathologic diagnoses were made according to well-established criteria for AD (15, 16), AGD (17), FTLD-tau (18), FTLD-U and FTLD-MND (19, 20), PD (21), DLB (20-23), and PiD (24, 25). Clinical and neuropathologic data are summarized in Table 2.
HeLa and SH-SY5Y cells were maintained in Dulbecco minimal essential medium (Invitrogen, El Prat de Llobregat, Spain) supplemented with 10% fetal bovine serum and 2 mmol/L L-glutamine. Both cell lines were grown at 37°C in a humidified atmosphere of 5% carbon dioxide.
DNA Purification and Bisulfite Treatment
Genomic DNA from human postmortem frozen brain samples was purified using DNeasy Tissue kit (Qiagen, Las Matas, Madrid, Spain) following the indications of the supplier. Bisulfite DNA treatment was performed using EZ DNA Methylation kit (Zymo Research, Ecogen, Barcelona, Spain). One microgram of genomic DNA for every sample was mixed with 5 μL of M-dilution buffer in a final volume of 50 μL and incubated at 37°C for 15 minutes. After incubation, 100 μL of prepared CT conversion reagent was added to each sample. The tubes were then incubated in the dark with a thermal cycler (GeneAmp PCR System 9700, Applied Biosystems, Madrid, Spain) as follows: 20 cycles at 95°C for 30 seconds and 50°C for 15 minutes followed by a last hold at 4°C for 10 minutes (the total duration is approximately 5.5 hours). The samples were then mixed with 400 μL of M-binding buffer and loaded into a Zymo-Spin I column and centrifuged (≥10,000 × g) for 30 seconds. The columns were washed with 200 μL of M-wash buffer and centrifuged at full speed for 30 seconds. After this, 200 μL of M-desulphonation buffer was added at room temperature for 15 minutes. After incubation, the columns were centrifuged at full speed for 30 seconds and then washed twice with 200 μL of M-wash buffer at full speed for 30 seconds and 1 minute. A third centrifugation without buffer was performed to remove wash buffer residues. Finally, 100 μL of water was added to the column, and DNA was eluted in a new tube after a centrifugation at 3,000 × g for 30 seconds.
Quantitative DNA Methylation Analysis
DNA regions surrounding transcriptional start sites of RAGE, ADORA2A, UCHL1, MAPT, PSEN1, and APP (26-33) were analyzed. Primers for each region were designed using MethPrimer (http://www.urogene.org/methprimer/). Each reverse primer presented a T7 promoter tagged to obtain an appropriate product for in vitro transcription and an 8-bp insert to prevent abortive cycling. The forward primers contain a 10-mer tag to balance the polymerase chain reaction (PCR) primer length. The sequence of each primer used for amplification of bisulfite-treated DNA (tags incorporated are labeled in lower case and underlined) is indicated as follows:
RAGE: forward, 5′-aggaagagagAGAGTGGGGAATTTTTTTTATTAAAG-3′; reverse, 5′-cagtaatacgactcactatagggagaaggctCACCCCTAAATACTACCAACCTCTA-3′;
ADORA2A: forward, 5′-aggaagagagTTAGTTAGGTAGAGGAGTAGGTGGG-3′; reverse, 5′-cagtaatacgactcactatagggagaaggctCCACTCTAAACTCAAAACCAAAAAT-3′;
MAPT-640/-294: forward, 5′-aggaagagagTGTAATTGAGTTAGTTTGTTTTAAGT-3′; reverse, 5′-cagtaatacgactcactatagggagaaggctCCTCCTATAATTAAAATCTTTATATC-3′;
MAPT+1411/+1978: forward, 5′-aggaagagagTTTTTTGTTTTGTTTGTAGAGGTTA-3′; reverse, 5′-cagtaatacgactcactatagggagaaggctCACCTATAATTTCCATAACAATCCC-3′;
MAPT+54336/+54905: forward, 5′-aggaagagagttTTtggtggtgTagaaTaggagaT-3′;
PSEN1: forward, 5′-aggaagagagTGGGTTTAATTTATATAGGGGTTTT-3′; reverse, 5′-cagtaatacgactcactatagggagaaggctTAACTCAAATTCCTTCCAAACCA-3′;
APP-526/-234: forward, 5′-aggaagagagTTGTTGTTTTAATAAGTAAAGAAAATTTTA-3′; reverse, 5′-cagtaatacgactcactatagggagaaggctAAAAAAAATCTAAAACCAAAAAAAA-3′.
APP-2572/-2108: forward, 5′-aggaagagagTTTGATTAGGGAATGTGTTAGTGTT-3′; reverse, 5′-cagtaatacgactcactatagggagaaggctCTCCAAAATTACATACCCATAAAAC-3′.
UCHL1: forward, 5′-aggaagagagGTTTAAAATTAAAGATTTTATTAAAAGGAT-3′; reverse, 5′-cagtaatacgactcactatagggagaaggctATCTAAAAAACAAATACAAAAAAAA-3′.
For PCR amplification, 2 μL of bisulfite-treated DNA was used as a template, along with 1 μL of each primer 1 μmol/L, 0.04 μL dNTPs 25 mmol/L, 0.42 μL water, 0.5 μL 10× Hot Star buffer and 0.04 μL of Hot Star Taq Flexi polymerase (Qiagen). The reaction was carried out using the following parameters: 94°C for 15 minutes and 45 cycles of 94°C for 20 seconds, annealing temperature of every set of primers for 30 seconds (Table 3), 72°C for 1 minute, and a last hold at 72°C for 3 minutes. Then, 0.5 μL of every PCR product was checked in 1.5% agarose gel to confirm successful PCR amplification. The rest of the PCR product of each sample was sent to SEQUENOM (Hamburg, Germany) to be analyzed using the MassArray System platform (34, 35). This technology consists of the analysis of DNA methylation by gene-specific amplification of bisulfite-treated DNA followed by in vitro transcription, base-specific cleavage, and matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) analysis without cloning of the PCR products. Because CpG sites that are very close to each other cannot be differentiated in the MALDI-TOF analysis, the percentage of DNA methylation is considered to be the same for each.
UCHL1 methylation levels were quantified in non-UCHL1-expressed HeLa cells (28) versus UCHL1-expressed SH-SY5Y cells as positive and negative controls of the reaction (see Supplemental Figure 1, Supplemental Digital Content 1, http://links.lww.com/A1408).
Statgraphics Plus v5 software was used for statistical analysis.
DNA Methylation Is Preserved in Human Postmortem Brain Samples
The 4 CpG sites quantified in RAGE were highly methylated (especially CpG Site Numbers 4 and 5); this methylation profile was not modified with artificially prolonged postmortem delay up to 48 hours (Fig. 1A). Similar results were obtained for all 13 CpG sites in ADORA2A (Fig. 1B). The region analyzed, 5′ upstream region of Exon 0 in MAPT, which was predicted as a CpG island by MethPrimer software, was lightly methylated, and no increase in methylcytosine content was observed with a progressive postmortem delay (Fig. 1C).
Analysis of DNA Methylation in Noncoding Regions of Genes Related With AD and Other Tauopathies
The percentages of DNA methylation were analyzed in 3 MAPT regions, a locus surrounding Exon 0 (Fig. 2) and 2 intronic loci (Figs. 3, 4). The analysis revealed low levels of DNA methylation in the 5′ upstream flanking region to Exon 0, only detecting around 20% to 40% of DNA methylation for CpG Sites 5, 6, and 13. No differences in the frontal cortex were detected between AD and tauopathies and age-matched control samples. Moreover, no differences were seen between these groups and other degenerative diseases, including FTLD-U, FTLD-MNS, PD, and DLB. Finally, no differences were observed in the hippocampus among different stages of AD, AGD, and age-matched controls (Fig. 2). The analysis of the other 2 MAPT regions in the intronic region close to and distant from Exon 0 was restricted to AD, tauopathies, and FTLD, and to AD and tauopathies, respectively. The analysis of the 3′ downstream flanking region to Exon 0 (positions at +1411/+1978 and at +54336/+54905) presented a technical problem because base-specific cleavage of the in vitro transcription product was not discriminated by MALDI-TOF, obtaining the same percentage of DNA methylation for CpG Site Numbers 3 and 7, CpG site Numbers 15 to 17 and 33 (Fig. 3), and CpG Site Numbers 1 and 19 (Fig. 4). The global DNA methylation profile for these 2 loci is similar to that observed in the 5′ upstream flanking region to Exon 0, including low levels of DNA methylation and no differences between control and diseased cases in the frontal cortex and hippocampus. The only difference occurred at Positions 1 and 19 in the +54336/+54905 region in PiD, where increased methylation was observed in comparison with controls (p < 0.01, analysis of variance with post hoc Scheffé test) (Fig. 4).
DNA methylation levels in the regions of PSEN1 analyzed were very low, and no differences were seen among controls and diseased cases in frontal cortex and hippocampus. Cases analyzed included AD, tauopathies, FTLD-U, FTLD-MNS, PD, DLBp, DLBc, and controls (Fig. 5).
Low CpG methylation in the APP gene promoter region close to the transcriptional start site occurred in control and diseased cases. No significant differences were seen among AD cases and cases with Lewy body-associated pathology (the only ones examined for APP); these did not differ from percentages of methylation encountered in controls (Fig. 6). In contrast, a high percentage of CpG methylation was present in a distal 5′ region of APP promoter. Again, no differences were seen among AD at different stages and Lewy body diseases (PD, DLBp, and DLBc) or between diseased cases and controls (Fig. 6).
A low percentage of DNA methylation was observed in controls. This pattern was not modified in PD, DLBp, and DLBc, although there were individual variations in Sites 6 to 8 and 16 to 18 (Fig. 7).
MassArray platform has been used to determine the percentage of DNA methylation in selected loci of gene promoters related to AD and other tauopathies. This technology consists of the analysis of DNA methylation by gene-specific amplification of bisulfite-treated DNA followed by in vitro transcription, base-specific cleavage, and MALDI-TOF without cloning of the PCR products. Although this is a robust method, it is worth stressing that CpG sites very close to each other cannot be differentiated in the MALDI-TOF analysis, and the percentage of DNA methylation is then considered to be the same for both. The MassArray technique does not evaluate non-CpG methylation (34, 35).
The genes for the study of possible effects of postmortem delay on CpG methylation were selected for several reasons. On 1 hand, DNA methylation in the RAGE promoter seems to be reduced with age (36), whereas the region analyzed in ADORA2A is heavily methylated. Finally, the region analyzed in MAPT is poorly methylated, and the selection of this gene was within the context of the study of genes-the encoded proteins of which are associated with AD. No modifications in CpG methylation with artificially increased postmortem delay up to 48 hours were observed in the regions examined in RAGE, ADORA2A, and MAPT. Recent studies have also shown that postmortem delay does not affect methylation of histone tails (37).
MAPT contains 16 exons and is devoid of TATA or CAAT boxes. A CpG island encompasses Exon 0 and spans more than 3 kb (29); 11 CpG islands are present in the adjacent Intron 0 (30). Previous studies have shown a decrease with age in the total number of methylcytosines in the 5′ flanking region close to Exon 0 in the human parietal cortex (38). Because 3 CpG islands analyzed here (one located upstream from Exon 0 and the other 2 in Intron 0) show a low percentage of DNA methylation in control and disease cases, this is difficult to assess. Interestingly, the same patterns were observed in control and disease cases, and similar methylation sites occurred in the frontal cortex and hippocampus. Moreover, no differences were seen among the different stages in AD or among AD, AGD, FTLD-tau, FTLD-U, FTL-MND, PD, DLBp, and DLBc. The only exception was PiD, in which increased DNA methylation was noted in CpG Sites 1 and 19. These results must be critically examined, however, first because the number of PiD cases was small, and second because in silico analysis did not reveal any putative binding for a transcription factor candidate in these particular sites as revealed by bioinformatic analysis with MatInspector software (see Supplemental Figure 2, Supplemental Digital Content 2, http://links.lww.com/A1409).
Recent studies have shown that PSEN1 is hypomethylated (11), and that no variations in DNA methylation are found in AD brains (39). We corroborate these findings at the different stages in AD, and we point out that modifications are also not observed in the other tauopathies, that is, FTLD-U and FTLD-MND, or in PD, DLBp, and DLBc.
APP is also GC rich, contains multiple initiation sites, and lacks a TATA box (33). Previous studies have shown a reduction in methylcytosines in the promoter region of APP with age, suggesting that demethylation may have some role in β-amyloid deposition in the aged brain (36, 40). These findings have not been replicated using a more sensitive technique in a larger number of cases, however (39). The present findings show no differences in the percentages of CpG methylation sites among different pathological conditions and age-matched controls.
Finally, a previous study revealed 35 CpG sites in the UCHL1 promoter, spanning the putative transcription start site and Exons 1 and 2; the gene promoter was fully methylated in non-UCHL1-expressed HeLa cells (28). Our study revealed that the UCHL1 promoter region has very low levels of DNA methylation in control samples. This finding correlates with the abundance of UCHL1 in the brain, constituting up to 2% of total protein (41). Inclusion of the study of UCHL1 in the present context was because previous studies demonstrated a reduced expression of UCHL1 mRNA and protein levels in the cerebral cortex in DLB (42), thus making CpG methylation at the UCHL1 promoter a putative mechanism of reduced UCHL1 mRNA expression and, therefore, a good candidate gene for comparative purposes. No differences in CpG methylation sites were observed in DLB cases when compared with controls.
Wang et al (39) recently reported 12 potential AD low-methylated loci in late-onset AD. Similar sites are observed in other neurodegenerative diseases including AGD, PiD, FTLD-tau, FTLD-U, FTLD-MND, PD, DLBp, and DLBc, indicating that putative sites are not exclusive to AD but rather are common in control and disease cases. Importantly, low methylation sites are susceptible to drug intervention. In this regard, putative binding sites to Sp1 and Ets family factors, such as Elk1, occur in the low-methylated −118/+178 region of PSEN1 (43, 44). Therefore, methylation by specific drugs might reduce the expression of PSEN1 and eventually curve β-amyloid deposition in AD. Indeed, S-adenosylmethionine administration in cell lines downregulates PSEN1 and reduces β-amyloid production and is thus a putative candidate for the treatment of AD (45, 46). Moreover, deprivation of S-adenosylmethionine upregulates PSEN1 and increases β-amyloid deposits in APP transgenic mice (47).
It is worth noting that the MAPT loci analyzed in the present study contain binding sites for Sp1, upstream stimulatory factor (USF1), XBP-1, ZNF219, heat-shock transcription factor 2, FAP-2, MAZ, Elk1, AP1, and NFKβ, and that all of these putative binding sites are hypomethylated. All of these transcription factors regulate tau expression (48-52) or have been implicated in brain function (53-58). ZNF219 is a member of the Kruppel-like zinc finger family that acts as a repressor (59), but its function in the central nervous system is not known.
The present findings in this very large number of cases and regions have shown the following: 1) preservation of CpG methylation of gene promoters with postmortem delay, thus enabling the study of DNA methylation in human postmortem brain; 2) highly reproducible methylation sites for a given gene in control and diseased cases in the human frontal cortex and hippocampus; and 3) a lack of significant modifications in the methylation state of selected loci in disease cases when compared with controls and among various pathological entities.
It is important to stress, however, that all of these studies were carried out in total homogenates of only relatively circumscribed areas that include presumed normal and damaged neurons and different populations of glial and other cells. Therefore, small changes in methylation of DNA promoters might have gone undetected. This caveat is particularly important in neurodegenerative diseases because they are long-lasting disorders in which small methylation changes might be sufficient to modulate their progression.
The authors thank Jesús Moreno and Salvador Juvés for excellent technical support in genomic DNA extraction, bisulfite DNA treatment, and analysis of PCR products in agarose gels. The authors also thank Dr S. Boluda for help in tissue sampling and T. Yohannan for editorial assistance.
1. Li E, Bird A. DNA methylation in mammals. In: Allis CD, Jenuwein T, Reinberg D, eds. Epigenetics
. New York, NY: Cold Spring Harbor Laboratory Press, 2007;341-56
2. Bird AP. CpG-rich islands and the function of DNA methylation. Nature 1996;321:209-13
3. Jones PA. The DNA methylation paradox. Trends Genet 1999;15:34-37
4. Tate PH, Bird AP. Effects of DNA methylation on DNA-binding proteins and gene expression. Curr Opin Genet Dev 1993;3:226-31
5. Lopez-Serra L, Esteller M. Proteins that bind methylated DNA and human cancer: Reading the wrong words. Br J Cancer 2008;98:1881-85
6. Nan X, Ng HH, Johnson CA, et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998;393:311-12
7. Amir RE, Van den Veyver IB, Wan M, et al. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet 1999;23:185-88
8. Weber M, Hellmann I, Stadler MB, et al. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet 2007;39:457-66
9. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-54
10. Ladd-Acosta C, Pevsner J, Sabunciyan S, et al. DNA methylation signatures within the human brain. Am J Hum Genet 2007;81:1304-15
11. Siegmund KD, Connor CM, Campan M, et al. DNA methylation in the human cerebral cortex is dynamically regulated throughout the life span and involves differentiated neurons. PLoS ONE 2007;2:e895
12. Ferrer I, Santpere G, Arzberger T, et al. Brain protein preservation largely depends on the postmortem storage temperature: Implications for study of proteins in human neurologic diseases and management of brain banks: A BrainNet Europe Study. J Neuropathol Exp Neurol 2007;66:35-46
13. Ferrer I, Armstrong J, Capellari S, et al. Effects of formalin fixation, paraffin embedding, and time of storage on DNA preservation in brain tissue: A BrainNet Europe Study. Brain Pathol 2007;17:297-303
14. Ferrer I, Martinez A, Boluda S, et al. Brain banks: Benefits, limitations and cautions concerning the use of post-mortem brain tissue for molecular studies. Cell Tissue Bank 2008;9:181-94
15. Braak H, Braak E. Temporal sequence of Alzheimer's disease related pathology. In: Peters A, Morrison JH, eds. Neurodegenerative and Age-Related Changes in Structure and Function of Cerebral Cortex
. New York, NY: Kluwer Academic/Plenum Publishers, 1999;475-512
16. Braak H, Alafuzoff I, Arzberger T, et al. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 2006;112:389-404
17. Ferrer I, Santpere G, van Leeuwen FW. Argyrophilic grain disease. Brain 2008;131:1416-32
18. Muñoz DG, Ferrer I. Neuropathology of hereditary forms of frontotemporal dementia and parkinsonism. In: Duyckaerts C, Litvan I, eds. Handbook of Clinical Neurology
, Vol 89: Dementias
. New York, NY: Elsevier, 2008;393-414
19. Kumar-Singh S, van Broeckhoven C. Frontotemporal lobar degeneration: Current concepts in the light of recent advances. Brain Pathol 2007;17:104-13
20. Cairns NJ, Bigio EH, Mackenzie IRA, et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: Consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol 2007;114:5-22
21. Braak H, Del Tredici K, Rüb U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211
22. Ince PG, McKeith I. Dementia with Lewy bodies. In: Dickson D, ed. Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders
. Basel, Switzerland: ISN Neuropath Press, 2003;188-99
23. McKeith I, Mintzer J, Aarsland D, et al. Dementia with Lewy bodies. Lancet Neurol 2004;3:19-28
24. Bergeron C, Morris HR, Rossor M. (2003) Pick's disease. In: Dickson D, ed. Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders
. Basel, Switzerland: ISN Neuropath Press, 2003;124-31
25. Uchihara T, Tsuchiya K. Neuropathology of Pick's disease. In: Duyckaerts C, Litvan I, eds. Handbook of Clinical Neurology
. New York, NY: Elsevier, 2008:415-30
26. Li J, Schmidt AM. Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J Biol Chem 1997;272:16498-506
27. Yu L, Frith MC, Suzuki Y, et al. Characterization of genomic organization of the adenosine A2A receptor gene by molecular and bioinformatics analyses. Brain Res 2004;1000:156-73
28. Bittencourt-Rosas SL, Caballero OL, Dong SM, et al. Methylation status in the promoter region of the human PGP9.5 gene in cancer and normal tissues. Cancer Lett 2001;170:73-79
29. Andreadis A, Wagner BK, Broderick JA, Kosik KS. A tau promoter region without neuronal specificity. J Neurochem 1996;66:2257-63
30. Poorkaj P, Kas A, D'Souza I, et al. A genomic sequence analysis of the mouse and human microtubule-associated protein tau. Mamm Genome 2001;12:700-12
31. Rogaev EI, Sherrington R, Wu C, et al. Analysis of the 5′ sequence, genomic structure, and alternative splicing of the presenilin-1 gene (PSEN1) associated with early onset Alzheimer disease. Genomics 1997;40:415-24
32. Mitsuda N, Roses AD, Vitek MP. Transcriptional regulation of the mouse presenilin-1 gene. J Biol Chem 1997;272:23489-97
33. Salbaum JM, Weidemann A, Lemaire HG, et al. The promoter of Alzheimer's disease amyloid A4 precursor gene. EMBO J 1988;7:2807-13
34. Ehrich M, Zoll S, Sur S, van den Boom D. A new method for accurate assessment of DNA quality after bisulfite treatment. Nucleic Acids Res 2007;35:e29
35. Ehrich M, Nelson MR, Stanssens P, et al. Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc Natl Acad Sci USA 2005;102:15785-90
36. Tohgi H, Utsugisawa K, Nagane Y, et al. Reduction with age in methylcytosine in the promoter region -224 approximately -101 of the amyloid precursor protein gene in autopsy human cortex. Brain Res Mol Brain Res 1999;70:288-92
37. Stadler F, Kolb G, Rubusch L, et al. Histone methylation at gene promoters is associated with developmental regulation and region-specific expression of ionotropic and metabotropic glutamate receptors in human brain. J Neurochem 2005;94:324-36
38. Tohgi H, Utsugisawa K, Nagane Y, et al. The methylation status of cytosines in a tau
gene promoter region alters with age to downregulate transcriptional activity in human cerebral cortex. Neurosci Lett 1999;275:89-92
39. Wang SC, Oelze B, Schumacher A. Age-specific epigenetic drift in late-onset Alzheimer's disease. PLoS ONE 2008;3:e2698
40. West RL, Lee JM, Maroun LE. Hypomethylation of the amyloid precursor protein gene in the brain of an Alzheimer's disease patient. J Mol Neurosci 1995;6:141-46
41. Solano SM, Miller DW, Augood SJ, et al. Expression of α-synuclein, parkin, and ubiquitin carboxy-terminal hydrolase L1 mRNA in human brain: Genes associated with familial Parkinson's disease. Ann Neurol 2000;47:201-10
42. Barrachina M, Castaño E, Dalfó E, et al. Reduced ubiquitin C-terminal hydrolase-1 expression levels in dementia with Lewy bodies. Neurobiol Dis 2006;22:265-73
43. Pastorcic M, Das HK. An upstream element containing an ETS binding site is crucial for transcription of the human presenilin-1 gene. J Biol Chem 1999;274:24297-307
44. Pastorcic M, Das HK. Ets transcription factors ER81 and Elk1 regulate the transcription of the human presenilin 1 gene promoter. Brain Res Mol Brain Res 2003;113:57-66
45. Scarpa S, Fuso A, D'Anselmi F, Cavallaro RA. Presenilin 1 gene silencing by S-adenosylmethionine: A treatment for Alzheimer disease? FEBS Lett 2003;541:145-48
46. Fuso A, Seminara L, Cavallaro RA, et al. S-adenosylmethionine/homocysteine cycle alterations modify DNA methylation status with consequent deregulation of PS1 and BACE and beta-amyloid production. Mol Cell Neurosci 2005;28:195-204
47. Fuso A, Nicolia V, Cavallaro RA, et al. S. B-vitamin deprivation induces hyperhomocysteinemia and brain S-adenosylhomocysteine, depletes brain S-adenosylmethionine, and enhances PS1 and BACE expression and amyloid-beta deposition in mice. Mol Cell Neurosci 2008;37:731-46
48. Heicklen-Klein A, Ginzburg I. Tau promoter confers neuronal specificity and binds Sp1 and AP-2. J Neurochem 2000;75:1408-18
49. Santpere G, Nieto M, Puig B, Ferrer I. Abnormal Sp1 transcription factor expression in Alzheimer disease and tauopathies. Neurosci Lett 2006;397:30-34
50. Citron BA, Dennis JS, Zeitlin RS, Echevarria V. Transcription factor Sp1 dysregulation in Alzheimer's disease. J Neurosci Res 2008;86:2499-504
51. Parks CL, Shenk T. The serotonin 1a receptor gene contains a TATA-less promoter that responds to MAZ and Sp1. J Biol Chem 1996;271:4417-30
52. Okamoto S, Sherman K, Bai G, Lipton SA. Effect of the ubiquitous transcription factors, SP1 and MAZ, on NMDA receptor subunit type 1 (NR1) expression during neuronal differentiation. Brain Res Mol Brain Res 2002;107:89-96
53. Kovacs DM, Wasco W, Witherby J, et al. The upstream stimulatory factor functionally interacts with the Alzheimer amyloid beta-protein precursor gene. Hum Mol Genet 1995;4:1527-33
54. Paschen W, Hotop S, Aufenberg C. Loading neurons with BAPTA-AM activates xbp1 processing indicative of induction of endoplasmic reticulum stress. Cell Calcium. 2003;33:83-89
55. Brown IR, Gozes I. Stress genes in the nervous system during development and aging diseases. Ann N Y Acad Sci 1998;851:123-28
56. Iwata A, Miura S, Kanazawa I, et al. α-Synuclein forms a complex with transcription factor Elk-1. J Neurochem 2001;77:239-52
57. Kaltschmidt B, Uherek M, Volk B, et al. Transcription factor NF-kappaB is activated in primary neurons by amyloid beta peptides and in neurons surrounding early plaques from patients with Alzheimer disease. Proc Natl Acad Sci U S A 1997;94:2642-47
58. Ferrer I, Martí E, López E, Tortosa A. NF-kB immunoreactivity is observed in association with beta A4 diffuse plaques in patients with Alzheimer's disease. Neuropathol Appl Neurobiol 1998;24:271-77
59. Sakai T, Hino K, Wada S, Maeda H. Identification of the DNA binding specificity of the human ZNF219 protein and its function as a transcriptional repressor. DNA Res 2003;10:155-65
This article has been cited 6 time(s).
EpigenomicsGene x environment interaction by a longitudinal epigenome-wide association study (LEWAS) overcomes limitations of genome-wide association study (GWAS)Epigenomics
Neuroscience5-Lipoxygenase and Epigenetic Dna Methylation in Aging Cultures of Cerebellar Granule CellsNeuroscience
Progress in NeurobiologyEpigenetic regulation in the pathophysiology of Alzheimer's diseaseProgress in Neurobiology
Journal of NeurochemistryDNA methylation regulates adenosine A(2A) receptor cell surface expression levelsJournal of Neurochemistry
Pharmacology & TherapeuticsEpigenetics: A novel therapeutic approach for the treatment of Alzheimer's diseasePharmacology & Therapeutics
Neuromolecular MedicineIncreased 5-Methylcytosine and Decreased 5-Hydroxymethylcytosine Levels are Associated with Reduced Striatal A(2A)R Levels in Huntington's DiseaseNeuromolecular Medicine
ADORA2A; APP; DNA methylation; MAPT; PSEN1; RAGE; UCHL1
Supplemental Digital Content
© 2009 American Association of Neuropathologists, Inc
What does "Remember me" mean?
By checking this box, you'll stay logged in until you logout. You'll get easier access to your articles, collections,
media, and all your other content, even if you close your browser or shut down your
To protect your most sensitive data and activities (like changing your password),
we'll ask you to re-enter your password when you access these services.
What if I'm on a computer that I share with others?
If you're using a public computer or you share this computer with others, we recommend
that you uncheck the "Remember me" box.
Highlight selected keywords in the article text.
Data is temporarily unavailable. Please try again soon.
Readers Of this Article Also Read